Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
13 Nov 2024
// BUSINESSWIRE
11 Nov 2024
// BUSINESSWIRE
24 Oct 2024
// BUSINESSWIRE
07 Aug 2024
// BUSINESSWIRE
05 Aug 2024
// BUSINESSWIRE
04 Jun 2024
// BUSINESSWIRE
Details:
OMS906 (zaltenibart) is a MASP-3 inhibitor, antibody candidate, which is currently being evaluated for the treatment of complement 3 glomerulopathy.
Lead Product(s): Zaltenibart
Therapeutic Area: Nephrology Brand Name: OMS906
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2024
Lead Product(s) : Zaltenibart
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Rare Pediatric Disease Status to Omeros’ Zaltenibart for C3G
Details : OMS906 (zaltenibart) is a MASP-3 inhibitor, antibody candidate, which is currently being evaluated for the treatment of complement 3 glomerulopathy.
Brand Name : OMS906
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2024
Details:
OMS721 (Narsoplimab) is a MASP-2 inhibitor that targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Lead Product(s): Narsoplimab
Therapeutic Area: Nephrology Brand Name: OMS721
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Lead Product(s) : Narsoplimab
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (Narsoplimab) is a MASP-2 inhibitor that targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopath...
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 16, 2023
Details:
OMS906 is a humanized mAb which inhibits MASP-3, the key activator of the alternative pathway of complement, it is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and other related indications.
Lead Product(s): OMS906
Therapeutic Area: Rare Diseases and Disorders Brand Name: OMS906
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Lead Product(s) : OMS906
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS906 is a humanized mAb which inhibits MASP-3, the key activator of the alternative pathway of complement, it is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and other related indication...
Brand Name : OMS906
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 25, 2023
Details:
The funding will be used to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
Lead Product(s): OMS527
Therapeutic Area: Psychiatry/Psychology Brand Name: OMS527
Study Phase: Phase IProduct Type: Small molecule
Sponsor: National Institute on Drug Abuse
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Funding April 10, 2023
Lead Product(s) : OMS527
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : National Institute on Drug Abuse
Deal Size : $6.6 million
Deal Type : Funding
Details : The funding will be used to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
Brand Name : OMS527
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 10, 2023
Details:
Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Ophthalmology Brand Name: Omidria
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Rayner
Deal Size: $1,326 million Upfront Cash: $126.0 million
Deal Type: Divestment February 06, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Rayner
Deal Size : $1,326 million
Deal Type : Divestment
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : $126.0 million
February 06, 2023
Details:
Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Lead Product(s): Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Neurology Brand Name: Omidria
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: DRI Healthcare Acquisitions
Deal Size: $188.4 million Upfront Cash: Undisclosed
Deal Type: Agreement October 03, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : DRI Healthcare Acquisitions
Deal Size : $188.4 million
Deal Type : Agreement
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
Details : Under the Royalty Purchase Agreement, DRI is entitled to royalties on net sales of OMIDRIA (having phenylephrine) received between September 1, 2022 and December 31, 2030, subject to annual caps.
Brand Name : Omidria
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 03, 2022
Details:
OMS721 (narsoplimab) was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients.
Lead Product(s): Narsoplimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: OMS721
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (narsoplimab) was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2022
Details:
OMS721 (narsoplimab) was selected for inclusion in the I-SPY COVID Trial because of its demonstrated ability to inhibit complement activation, inflammation, and coagulation, the three components that characterize COVID-19.
Lead Product(s): Narsoplimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: OMS721
Study Phase: Phase IIIProduct Type: Large molecule
Recipient: Quantum Leap Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Quantum Leap Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OMS721 (narsoplimab) was selected for inclusion in the I-SPY COVID Trial because of its demonstrated ability to inhibit complement activation, inflammation, and coagulation, the three components that characterize COVID-19.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2022
Details:
OMS906 is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.
Lead Product(s): OMS906
Therapeutic Area: Rare Diseases and Disorders Brand Name: OMS906
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2022
Lead Product(s) : OMS906
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysma...
Details : OMS906 is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway.
Brand Name : OMS906
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 29, 2022
Details:
Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
Lead Product(s): Narsoplimab
Therapeutic Area: Hematology Brand Name: OMS721
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Lead Product(s) : Narsoplimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
Brand Name : OMS721
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 20, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?